Product
Neoadjuvant anti-PD-1
2 clinical trials
3 indications
Indication
Esophageal cancerIndication
Esophageal squamous cell carcinomaIndication
Neoadjuvant ChemoimmunotherapyClinical trial
Neoadjuvant PD-1 Blockade (Toripalimab) Monotherapy for Elderly Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: a Phase II TrialStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Single-center, Prospective Cohort Study of Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2023-12-01